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Cooperation between STAT3 and c-Jun results in sup-
pression of Fas Receptor (FasR) transcription, which is
often seen in advanced human tumors. To identify re-
quirements for STAT3-Jun cooperation, we elucidated
the role of protein kinases that affect both transcription
factors. The phosphatidylinositol 3-kinase (PI3K)-AKT
signaling pathway was found capable of down-regulat-
ing both STAT3- and c-Jun-dependent transcription, re-
sulting in derepression of FasR transcription. Con-
versely, inhibition of PI3K-AKT signaling via the
specific pharmacological inhibitor LY294002 up-regu-
lated AP1/Jun- and STAT-dependent transcriptional ac-
tivities, resulting in suppression of the FasR promoter
activities and decreased FasR surface expression. PI3K-
AKT’s ability to affect FasR transcription was not ob-
served in c-jun null fibroblasts, suggesting that c-Jun is
required for PI3K/AKT-mediated regulation of FasR
transcription. Interestingly, the dominant negative
form of Rac1 (RacN17) was also efficient in relieving
FasR expression, suggesting that the increase in FasR
expression following AKT stimuli could be mediated via
AKT ability to elicit suppression of Rac1, which in turn
decreases JNK activities and c-Jun phosphorylation.
Overall, our findings demonstrate that through its neg-
ative effects on both c-Jun and STAT3, the PI3K-AKT
pathway disrupts cooperation between c-Jun and
STAT3, which is required for silencing the FasR pro-
moter, resulting in increased expression of surface FasR
and concomitant sensitization to FasL-mediated pro-
grammed cell death.
Deregulation of cell proliferation and suppression of apopto-
sis meet the essential requirements for neoplastic development
and progression. Understanding the multiple regulatory ele-
ments that are impaired in human tumors highlights the com-
plexity of controlled cell growth while pointing to targets that
may be impaired during tumor development. Both normal and
tumor cells use the PI3K-AKT1 (protein kinase B) as survival
pathways that utilize several critical cellular effectors as sub-
strates and modulators of the cell’s ability to undergo apoptosis
(1–3). These include phosphorylation-dependent inhibition of
proapoptotic signals of proteins such as BAD, caspase 9, and
the family of forkhead transcription factors (4–6). Addition-
ally, AKT enhances survival signals via activation of NF-B-
dependent expression of anti-apoptotic genes, including FLIP
and c-IAPs, and suppresses mitochondrial pathways required
for apoptosis (7–9). Certain tumors increase AKT expression,
activity, or both as a means of escaping programmed cell death.
For example, AKT was found to be overexpressed in breast
cancer cell lines and in ovarian and pancreatic cancers and
amplified in gastric adenomas (10–13). Expression of down-
stream antiapoptotic factors, such as inhibitors of apoptosis
(IAPs), is altered in human tumors; ML-IAP is an example for
a member of the family of IAPs, which is preferentially ex-
pressed in human melanoma (14). Expression of survivin and
Bcl2 are also modified in the course of tumor development (15,
16). Apaf1, a cell death effector that acts with cytochrome c and
caspase 9 to mediate stress-dependent apoptosis, is inactivated
in 40% of malignant melanomas, thereby providing another
example for a modification of an apoptotic cascade that ac-
quires malignant melanoma with chemoresistance (17).
Changes in the proapoptotic signaling were also documented
during tumor development and progression. Each of the six
major cell death pathways, TNFR1, FasR, TRAIL-R1, TRAIL-
R2, DR3, and DR6, were reported to undergo certain changes in
the course of tumor progression (18). Fas Receptor (Fas, CD95/
Apo-1) signaling appears to serve as a primary death cascade in
human melanomas (19). Upon interacting with Fas Ligand,
FasR forms a complex with the Fas-associated death domain
protein, which directly binds and activates caspase 8, resulting
in the induction of apoptosis (20, 21). FasR ligation also induces
a rapid and transient tyrosine phosphorylation, which coin-
cides with PI3K/AKT activation and is required for Fas medi-
ated apoptosis (22). Tyrosine phosphorylation was found essen-
tial for FasR-mediated apoptosis (23, 24).
Several studies point to the relationship between pro- and
antiapoptotic cell death signaling (i.e. PI3K-AKT and Fas).
PI3K is among signaling pathways implicated in the regulation
of FasR responses (25). UV irradiation-mediated activation of
PI3K signaling via epidermal growth factor receptors in human
skin provides an example for physiological stimuli that utilize
the PI3K/AKT cascade to affect the degree of damage-induced
cell death (26). UV, via generation of hydrogen peroxide, in-
duces AKT phosphorylation (27). Overall increase in basal lev-
els of PI3K/AKT activity coincided with tumor cell ability to
exhibit resistance to UV and ionizing radiation (28, 29).
Impaired Fas signaling is frequently observed during tumor
progression and has been attributed in most cases to down-
regulation of Fas expression (30, 31). Loss of Fas function has
been implicated in increased resistance of tumors to apoptosis
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induced by chemical and physical stimuli and is thought to
represent one of the mechanisms that enable such tumors to
escape immune surveillance as well as to acquire the meta-
static phenotype (32–37). Whereas regulation of fas transcrip-
tion is mediated by both constitutive and inducible regulatory
pathways, down-regulation of Fas expression in advanced hu-
man melanoma-derived cell lines was found to be mediated by
cooperation of STAT3 with c-Jun, a process that can be most
clearly identified in advanced tumors. Interference with such
cooperation through the use of dominant negative forms of
either STAT3 or c-Jun efficiently restored transcription and
surface expression of FasR (38). In our search for signaling
pathways that could control such cooperation, we discovered
the role of PI3K/AKT, which we report here.
Concomitant with elevated PI3K-AKT activities in human
tumors is increased survival, motility, and metastatic capacity
(39–44). Here we demonstrate that AKT is also capable of
altering the activities of transcription factors that play impor-
tant roles in regulating FasR expression. In demonstrating
that AKT signaling plays an important role in controlling FasR
expression, we document a novel layer of regulation that links
the PI3K-AKT pathway with Fas-mediated death in tumor
cells, which represents an important mechanism in the control
of tumor development and progression.
EXPERIMENTAL PROCEDURES
Materials—PD98059, SB203580, AG490, and LY294002 were ob-
tained from Calbiochem. Final concentrations used were 50 M
PD98059, 10 M SB203580, 50 M AG490, and 50 M LY294002.
Cell Lines—Human melanoma cells were kindly provided by Drs. M.
Herlyn and O. Fodstad and maintained in culture as previously de-
scribed (45, 46). Embryonic stem cells E14 (STAT3/) and E14 clone
3–2 (STAT3/) were kindly provided by Dr. D. Levy of New York
University; these cultures were propagated by standard methods on
monolayers of mitomycin C-treated mouse fibroblasts (47). Normal
mouse fibroblasts (c-jun/), (c-jun/) fibroblasts were a kind gift of
Dr R. Wisdom; mouse melanoma cells were kindly provided by L.
Owen-Schwab and were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum.
Plasmid Constructs—The Fas promoter reporter constructs (1.7 kb
Fas-Luc and 460 Fas-Luc) were previously described (48). Mutations
within the GAS or AP1 site and deletion of the 24-bp sequence contain-
ing both AP1 and GAS elements were generated using the QuikChange
kit (Stratagene) and were previously described (38). The expression
plasmid pIRES-STAT3, which encodes the human STAT3 (49), was
kindly provided by Dr. R. Jove. WM9, WM793, and LU1205 cells stably
transfected with STAT3 were previously described (38). The expres-
sion vector of permanently active AKT (HA-AKT-myr) was kindly pro-
vided by Dr. P. Tsichlis. The expression vectors of active form of PI3K
(p110 subunits) was obtained from Dr. L. Williams (50). The dominant
negative form of PI3K (p85 subunits) was previously described (51);
PTEN expression vector (52) was kindly provided by Dr. A. Chan. WM9
cells were permanently transfected with p110, p85, AKT-myr, or
PTEN expression vectors. Transfected cultures were subjected to selec-
tion in G418 (200 g/ml) or puromycin (2 g/ml) as indicated under
“Results,” and a mixed population of resistant cells was analyzed.
Transient Transfection and Luciferase Assay—The luciferase re-
porter gene containing five TRE elements from the c-Jun promoter
(5Jun2-tk-Luc) or three GAS elements from the Ly6E gene (3Ly6E-
Luc) as target sequences for c-Jun and STAT3, respectively, were pre-
viously described (38, 53). Transient transfection of different reporter
constructs (0.5 g) together with expression vectors and pCMV-gal
(0.25 g) into 5  105 melanoma cells was performed using Lipo-
fectAMINE (Invitrogen). Proteins were prepared for -galactosidase
and luciferase analysis 18 h after transfection. Luciferase activity was
determined using the luciferase assay system (Promega) and normal-
ized based on -galactosidase levels.
Treatment and Apoptosis Studies—Cells were exposed to UVC at 60
J/m2 as previously described (54). FasL (25–50 ng/ml) was used in com-
bination with cycloheximide (10 g/ml). Apoptosis was assessed by quan-
tifying the percentage of hypodiploid nuclei undergoing DNA fragmenta-
tion (55). Surface expression of Fas was determined using anti-Fas-PE Ab
(Pharmingen). Flow cytometric analysis was performed on a FACS Cali-
bur flow cytometer (Becton Dickinson) using the CellQuest program.
Transient Transfection and GFP Assay—Melanoma cells (5  105)
were transiently co-transfected with expression vectors together with
marker plasmid encoding green fluorescent protein (pGFP; 1 and 0.25
g, respectively) using LipofectAMINE (Invitrogen). 24 h after trans-
fection, surface Fas expression in GFP-positive cells was determined by
staining with PE-anti-Fas Ab and flow cytometry. For apoptosis stud-
ies, cells were irradiated with UVC (60 J/m2) 24 h after transfection and
18 h later were stained with propidium iodide and analyzed by flow
cytometry.
Western Blot Analysis—Cell lysates (50–100 g of protein) were
resolved on 10% SDS-PAGE and processed according to the standard
protocols. The Abs used were anti-phospho-AKT (Ser473), anti-phospho-
JNK (Thr183/Tyr185), anti-phospho-c-Jun (Ser73), anti-phospho-STAT3
(Tyr705), and anti-phospho-p38 (Thr180/Tyr182), and corresponding con-
trol Abs were obtained from Cell Signaling and used at dilutions of
1:1000 to 1:3000. The secondary Abs (anti-rabbit or anti-mouse) conju-
gated to horseradish peroxidase (dilution 1:5000). Signals were detected
using the ECL system (Amersham Pharmacia Biotech).
Oligonucleotides and Protein Binding Assay—Double-stranded bioti-
nylated oligonucleotides used in this study were derived in wild type
and mutant configurations from the Fas promoter sequences: WT (Bi-
otin-AAT GCC CAT TTG TGC AAC GAA CCC TGA CTC CTT CCT),
mutated GAS, and AP1 sites (Biotin-AAT GCC CAT TTG TGC TTC
GAA CCC AAA CTC CTT CCT). Nuclear proteins were prepared, as
previously described (56). Nuclear proteins (400 g) were incubated
with biotinylated oligonucleotides in solution followed by coupling of
oligonucleotides and their bound proteins to Streptavidin-agarose
(Stratagene); bead-bound material was subjected to extensive washes
before specifically associated proteins were eluted in SDS-loading
buffer and separated on SDS-PAGE followed by Western blotting with
Abs against phospho-STAT3 (Tyr705), phospho-c-Jun (Ser73), and corre-
sponding control Abs.
RESULTS
The PI3K/AKT Pathway Positively Regulates FasR Expres-
sion via Suppression of STAT3 and c-Jun—Cooperation be-
tween STAT3 and c-Jun suppresses Fas receptor (FasR) tran-
scription and subsequent FasR expression on the cell surface,
as often seen in advanced tumors. To elucidate mechanisms
underlying the cooperation between two ubiquitously ex-
pressed transcription factors that results in silencing FasR
transcription and expression, we explored the possible role of
protein kinases, which affect both STAT3 and c-Jun. To this
end, we monitored the effect of pharmacological inhibitors of
the PI3K-AKT pathway (LY294002) and the mitogen-activated
protein kinase/extracellular signal-regulated kinase pathway
(PD98059) as well as of mitogen-activated protein kinase p38/
JNK (SB203580) and JAK (AG490) on cell surface expression of
Fas receptor (FasR) (Fig. 1A). Of the inhibitors used, only
LY294002 resulted in a marked decrease (60%) in surface FasR
expression in WM9 and WM793 cells and to a lesser extent
(20%) in LU1205 cells. These results imply that the PI3K/AKT
signaling cascade positively regulates expression of FasR and
that inhibition of this pathway results in decreased FasR ex-
pression on the cell surface. Additionally, a notable decrease of
surface Fas expression after LY294002 treatment was observed
for the early melanoma cell lines WM1650 and WM35 (not
shown). It is of interest that LU1205 cells also exhibited in-
creases in FasR levels in response to inhibition of p38/JNK,
suggesting that p38/JNK negatively regulates FasR expression
in these cells. Western blot analysis confirmed down-regulation
of total Fas levels in these cell lines (not shown). The three
melanomas selected for the initial analysis included early
phase melanoma cells WM9 and WM793 and the late phase
melanoma LU1205 cells. Of these cell lines, LU1205 was found
to express a truncated form of the PTEN protein indicative of
mutated PTEN (data not shown). Mutated PTEN is expected to
result in constitutively active PI3K/AKT signaling, which
would explain the limited inhibition observed in the LU1205
cells after LY294002 treatment.
To further explore the role of PI3K/AKT in regulating FasR
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expression, we monitored changes in the STAT- and AP1/Jun-
dependent transcriptional activities. Using the luciferase re-
porter gene that is under the control of AP1/c-Jun (5Jun2-tk-
Luc) or STAT (3Ly6E-Luc) target sequences, we observed an
increase (2–3-fold) in the level of STAT and Jun-dependent
transcriptional activities in both WM9 and LU1205 cells after
LY294002 treatment. Increased Jun and STAT transcriptional
activities coincided with a 50–80% decrease in FasR-Luc ac-
tivities (Fig. 1B). These findings suggest that PI3K elicits neg-
ative regulatory effects on both STAT and c-Jun transcription
factors, as inhibition of this signaling cascade results in in-
creased transcriptional activities of both transcription factors
and concomitant suppression of the FasR promoter.
Using WT and mutated forms of the FasR promoter, we
further monitored the effect of PI3K/AKT signaling on FasR
promoter activity. FasR promoter mutated on the GAS element
(which serves as the target sequence for STAT proteins) exhib-
ited a 40% inhibition in FasR-Luc activity compared with the
80% inhibition seen with the WT promoter following LY294002
treatment (Fig. 1C). This finding suggests that the GAS ele-
ment contributes to PI3K-mediated derepression of FasR tran-
scription. Mutation within the AP1 site completely abolished
the ability of LY294002 to suppress FasR transcription, sug-
gesting that AP1 is essential for PI3K/AKT-mediated derepres-
sion of FasR promoter activity. Similarly, deletion of the AP1
and GAS elements from the FasR promoter sequences attenu-
ated LY294002’s ability to suppress FasR transcription, result-
ing in increased FasR transcription in the WM9 melanoma
cells. Unlike AP1 and GAS elements, the NF-B site did not
appear to play a role in the regulation of FasR promoter by
AKT/PI3K, since mutations of NF-B binding site did not affect
LY294002’s ability to suppress FasR promoter activities (Fig.
1C). Together, this analysis reveals that PI3K/AKT utilizes
transcription factor binding to the AP1 and GAS motives on the
FasR promoter to mediate derepression of the promoter activ-
ities in these melanoma cells.
Analysis of STAT3 and c-Jun phosphorylation revealed a
noticeable increase in the serine phosphorylation of both c-Jun
and STAT3 in cells that were treated with LY294002 (Fig. 1D).
Since an increase in serine phosphorylation of both transcrip-
tion factors is a prerequisite for their transcriptional activities,
this observation reveals how silencing of FasR is alleviated in
the presence of the pharmacological inhibitor of PI3K. It is
important to note that tyrosine phosphorylation of STAT3 was
altered in one of the two melanomas tested here, suggesting
that it may not reveal the primary mechanism for the changes
seen upon LY29004 treatment (Fig. 1D). As indicated in former
studies, it is sufficient to alter one of the two transcription
factors in order to positively affect FasR transcription (38).
Along these lines, in earlier studies, we demonstrated the
ability to increase FasR surface expression upon constitutive
expression of dominant negative STAT3 or c-Jun (38). Treat-
ment of melanoma cells that constitutively express STAT3,
the dominant negative form of STAT3, which efficiently in-
creased FasR expression, with the pharmacological inhibitor of
PI3K, efficiently suppressed FasR surface expression in all
three melanoma lines (Fig. 1E). This finding provides addi-
tional support for the role of STAT3 as a target for PI3K
regulation of FasR expression.
To further assess the effect of LY29004 on STAT3, we have
monitored possible changes in the tyrosine phosphorylation of
STAT3 under these experimental conditions. LY29004 caused
an additional increase in the levels of STAT3 ( and  forms)
without affecting the levels of STAT3 tyrosine phosphorylation
in control WM9-neo cells (lanes 1–3 in Fig. 1F). Time-depend-
ent increase in STAT3 forms without a corresponding increase
in their tyrosine phosphorylation resulted in decreased FasR
expression (Fig. 1E). Forced expression of STAT3 was accom-
panied by tyrosine phosphorylation of STAT3 and - forms
FIG. 1. The PI3K inhibitor LY294002 down-regulates surface
Fas expression and Fas promoter activities in human melanoma
cell lines. A, effect of inhibition of distinct signaling pathways by
PD98059 (50 M), AG490 (50 M), LY294002 (50 M), and SB203580 (5
M) on Fas surface expression in the indicated melanoma cell cites. Cell
surface expression was determined by flow cytometric analysis (moni-
tored via MFI). B, LU1205 and WM9 melanoma cells were transfected
with 5Jun2-Luc (a reporter construct specific for AP-1-dependent
transcription), 3Ly6E-Luc (a reporter specific for STAT-dependent
transcription), and 460 Fas-Luc in the presence of pCMV--gal. Cells
were untreated (control) or treated with LY294002 (50 M) for an
additional 6 h. The data shown reflect changes over the control non-
treated cultures. In all cases, the normalized ratio of luciferase activity
to -galactosidase is shown. C, WM9 cells were transiently transfected
with 460 Fas-Luc and mutated variants of this construct in the
presence of pCMV--gal. LY294002 (50 M) was added to the cultures
16 h after transfection for an additional 6 h before cells were harvested
and proteins were analyzed for luciferase and -galactosidase activity.
The normalized ratio of luciferase activity to -galactosidase is shown.
D, analysis of STAT3 and c-Jun expression and phosphorylation in
WM9 and WM793 melanoma cells. Proteins were prepared from the
melanoma cells under mock treatment or 2 h after exposure to LY29004
and subjected to analysis with the corresponding antibodies as indi-
cated. The arrows point to the positions of the respective proteins. E,
cell surface Fas expression of the indicated melanoma cells (WM9,
LU1205, WM793 cells, and derivatives of these cell lines that had been
stably transfected with STAT3) was determined by staining with an
anti-Fas-PE mAb followed by flow cytometric analysis. Filled histo-
grams represent nonspecific (ns) staining with mouse Ig-PE. Empty
histograms represent control and LY294002-treated cells, as indicated.
The numbers reflect MFI values. F, STAT3 tyrosine phosphorylation in
WM9 cells. Analysis of tyrosine phosphorylation was carried out as
indicated in D, using proteins prepared from WM9 control or cells that
constitutively express STAT3. The arrows point to the positions of the
STAT3 and - forms. The image was enlarged to enable better sepa-
ration of the  and  forms.
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(Fig. 1F, lane 4) and increased FasR expression (Fig. 1E),
probably due to squelching of STAT3 by STAT3, thereby de-
creasing cooperation with c-Jun, which is required for silencing
of FasR transcription. Treatment of STAT3-transfected cells
with LY29004 decreased tyrosine phosphorylation of both
forms of STAT3, despite an increase in their expression (Fig.
1F, lanes 5 and 6), and resulted in decreased FasR expression
(Fig. 1E), similar to what was observed in the WM9 cells that
were subjected to LY29004 treatment without STAT3 expres-
sion (Fig. 1F, lanes 2 and 3, and Fig. 1E). These data suggest
that tyrosine phosphorylation of STAT3 is required to enable
its inhibitory effect on STAT3 and its ability to relieve FasR
suppression.
c-Jun Is Essential for PI3K/AKT Regulation of the FasR
Promoter—The finding that the AP1-mutated form of the FasR
promoter did not respond to PI3K inhibitor led us to directly
explore the role of c-Jun in PI3K/AKT regulation of the FasR
promoter. For this purpose, we used c-Jun null cells (57).
Whereas LY294002 elicited suppression of the FasR promoter
in normal mouse fibroblasts, forced expression of a constitu-
tively active form of PI3K (p110*) or AKT (AKTmyr) results in
efficient increase in FasR-Luc activities, while p85 (dominant
negative form of PI3K) negatively affected this activity, further
pointing to the positive role of PI3K/AKT in the regulation of
the FasR promoter. However, neither LY294002, p110*, AKT,
or p85 were able to alter the high basal levels of the FasR
promoter activities and surface FasR expression seen in the
c-jun/ fibroblasts (Fig. 2, A and B). These findings suggest
that c-Jun is indeed a key element in PI3K’s ability to regulate
FasR transcription.
To determine whether c-Jun must be phosphorylated in or-
der to affect FasR expression, we transfected the c-jun/ cells
with either WT or phosphoacceptor mutant forms of c-Jun. The
WT form of c-Jun efficiently reduced the level of FasR expres-
sion to a mean fluorescence intensity (MFI) of 95 (Fig. 2C).
Since transfection of the empty vector was sufficient to de-
crease basal FasR expression to 160 MFI, the relative decrease
that should be noted upon c-Jun expression is from 160 to 95
MFI. In contrast to the effect of WT c-Jun, c-Jun mutated on its
phosphoacceptor sites did not have any effect on FasR expres-
FIG. 2. Effect of LY294002 on Fas expression requires c-Jun. A, PI3K (p110*) or AKTmyr expression up-regulates Fas promoter activity in
normal mouse (cJun/) fibroblasts. Mouse fibroblasts (cJun/ or cJun/) were transiently cotransfected with 460 Fas-Luc and expression
vectors encoding active forms of PI3K (p110*), AKTmyr, or the dominant negative form of PI3K (p85). 16 h after transfection, LY294002 (50 M)
was added to the cultures for an additional 6 h. Then cells were analyzed for luciferase and -galactosidase activity. The normalized ratio of
luciferase activity to -galactosidase is shown. B, LY294002 failed to down-regulate surface Fas expression in c-jun/ mouse fibroblasts but
down-regulated Fas levels in normal c-jun/ fibroblasts. Cell surface Fas expression was determined by staining with an anti-Fas-PE mAb
followed by flow cytometric analysis. The numbers reflect MFI values. C, c-jun/ fibroblasts were transfected with empty vector (pBabe-puro),
c-Jun or mutated c-Jun-(63,73A) expression vectors. Puromycin-resistant cells were selected. Surface Fas expression was determined by staining
with an anti-Fas-PE mAb and flow cytometric analysis. MFI levels are indicated. ns, nonspecific band.
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sion, since the level of MFI was equal to those observed upon
expression of the empty vector (Fig. 2C). These findings suggest
that c-Jun must be phosphorylated on Ser63/Ser73 to be able to
reduce the FasR expression level.
AKT Mediates c-Jun Suppression via Down-regulation of
JNK Activity and c-Jun Phosphorylation—The finding that
c-Jun must be phosphorylated on Ser63/Ser73 if it is to possess
the capability of altering FasR transcription pointed to a plau-
sible connection between PI3K and JNK, which is the primary
c-Jun kinase in PI3K-dependent transcription of the FasR pro-
moter. To determine whether AKT alters JNK/Jun phosphoryl-
ation, we established three melanoma cultures that stably ex-
press AKTmyr. Analysis of protein extracts to determine the
effect of AKTmyr revealed a noticeable increase in expression
and phosphorylation levels of AKT in each of the three mela-
noma lines (Fig. 3A). Increased AKT activity coincided with a
decrease in the high basal levels of JNK, but not p38, phospho-
rylation (commonly seen in these melanomas) and c-Jun, as
well as STAT3 serine phosphorylation (Fig. 3A). These findings
suggest that AKT down-regulates JNK activity and conse-
quently c-Jun and STAT3 phosphorylation. AKT-expressing
melanoma cells also exhibited a marked increase in FasR tran-
scription (Fig. 3C). Like AKTmyr, p110* also increased Fas-Luc
activity. In contrast, p85 in its dominant negative form (p85)
and PTEN led to a marked decrease in Fas-Luc activities (Fig.
3C). It is important to note that forced expression of either
AKTmyr or p110* elevated the transcriptional activities of the
FasR promoter mutated on the NF-B site (Fig. 3C), suggesting
that the primary regulators of the FasR promoter by AKT are
c-Jun and STAT3. Indeed, level of c-Jun and STAT3 transcrip-
tional activities were inversely correlated with those observed
for the FasR promoter activity. AKTmyr and p110* expression
led to a decrease in c-Jun and STAT transcriptional activities
monitored via the 5Jun2-Luc and GAS-Luc constructs, re-
spectively. In contrast, their transcriptional activities in-
creased in response to PTEN and even more markedly follow-
ing expression of the dominant negative form of p85 (Fig. 3B).
These data suggest that AKT’s ability to increase FasR tran-
scription depends on down-regulation of JNK and consequently
c-Jun activities. Along with the changes in Jun and STAT
transcription were changes in the level of FasR surface expres-
sion. Forced expression of either AKTmyr or p110* increased
FasR cell surface expression (Fig. 3D). Conversely, forced ex-
pression of a dominant negative form of p85 as well as PTEN
caused a marked decrease in the expression of cell surface FasR
(Fig. 3D). In all cases, changes in the cell surface expression of
FasR coincided with altered FasR promoter activity.
Changes in STAT3 and c-Jun phosphorylation and transcrip-
tional activities following AKTmyr treatment was also moni-
tored at the level of FasR promoter-bound proteins. With the
aid of biotinylated oligonucleotides containing the GAS-AP1
element, as found on the FasR promoter (WT or mutated), we
monitored changes in binding of STAT3 and c-Jun. An associ-
ation of phosphorylated c-Jun and STAT3 to the FasR promot-
er-driven oligonucleotide was observed in normally growing
WM9 cells. In cells that express AKTmyr, there was a noticeable
decrease in binding of phosphorylated as well as the nonphos-
phorylated forms of both transcription factors (Fig. 3E). This
observation suggests that inhibition of STAT3 and c-Jun phos-
phorylation by AKT affects their association on the FasR pro-
moter, which is required to elicit FasR transcriptional silenc-
ing. Overall, these findings establish a link between PI3K/AKT
FIG. 3. Melanoma cell lines stably transfected with the active form of AKT (AKTmyr) exhibit suppression of JNK activity, c-Jun
phosphorylation, and an increase in Fas surface expression. A, Western blot analysis of the indicated melanoma cell lines transfected with
an empty vector or AKTmyr. Anti-P-AKT, control anti-AKT, anti-P-c-Jun, anti-c-Jun, anti-P-p38, anti-p38, anti-Tyr(P)-STAT3, and anti-STAT3
antibodies were used. B and C, WM9 cell lines stably expressing PI3K p110*, AKTmyr, p85, and PTEN were established; control WM9-neo cells
were stably transfected with empty vector pcDNA3. The indicated cell lines were additionally cotransfected with 460 Fas-Luc and its mutated
variants (C) or with 5Jun2-Luc, 3Ly6E-Luc, or 2NF-B-Luc constructs (B) in the presence of pCMV--gal. 16 h after transfection, cells were
analyzed for luciferase and -galactosidase activity. The normalized ratio of luciferase activity to -galactosidase is shown. D, surface Fas
expression of the indicated melanoma cell lines. Control Fas levels of WM9-neo cells (110 MFI) are indicated by the open black histogram, whereas
changes in Fas surface levels upon expression of the p110*, AKTmyr, p85, or PTEN are depicted as gray open histograms, with the respective MFI
values indicated. E, binding of STAT3 and c-Jun to AP1-GAS sites decreases in cells that express active AKT. Biotinylated oligonucleotides
containing GAS-AP1 element sites as present on the fas promoter (fas oligo) in WT or double mutants (as indicated) were incubated with nuclear
proteins of WM9 cells or of WM9-AKTmyr cells. Biotinylated oligonucleotide-bound proteins were captured on avidin-agarose beads and washed,
and GAS-AP1-bound proteins were eluted and analyzed on Western blotting with the control or phosphospecific Abs to c-Jun and STAT3. The
relative positions of the corresponding proteins are shown. ns, nonspecific band.
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and JNK/Jun in the negative regulation of FasR promoter
activities and, consequently, the FasR cell surface expression
levels.
AKT’s ability to alter FasR cell surface expression is inde-
pendent of caspase activities, since pretreatment of WM9 mel-
anoma cells with zVAD-fmk (a universal caspase inhibitor)
before the addition of LY294002 did not attenuate LY294002-
mediated down-regulation of Fas surface levels. Similarly,
treatment of the WM9 melanoma cells with rapamycin to sup-
press mTOR, a rapamycin-sensitive protein kinase that is reg-
ulated by the PI3K-AKT pathway and which participates in the
general control of translation in the cell, did not alter PI3K
effects on Fas surface expression (data not shown), further
indicating that the PI3K-AKT pathway regulates mainly the
FasR transcriptional activity.
TNF Increases FasR Expression via AKT Activation—Char-
acteristic of late phase melanoma cells is their constitutive
production of cytokines, enabling their autonomous growth. We
tested a classic cytokine, TNF, with regard to its effect on
FasR surface expression. Treatment of late stage melanoma
LU1205 cells with TNF resulted in an increase in the phos-
phorylated form of AKT (Fig. 4A). TNF also caused a marked
increase in the level of FasR cell surface expression that could
be effectively attenuated upon treatment with the pharmaco-
logical inhibitor of AKT, LY294002 (Fig. 4B). Given the effects
of TNF on NF-B activities, we also monitored changes in
FasR expression upon expression of IBN, an IB form that
lacks the amino-terminal domain required for its phosphoryl-
ation targeted degradation, thereby rendering IB highly sta-
ble, which consequently inhibits NF-B transcriptional activi-
ties. Forced expression of IBN slightly decreased the level of
FasR expression and partially blocked the ability of TNF to
increase FasR expression. However, despite expression of
IBN, TNF-mediated increase of FasR surface expression
was still attenuated by treatment with LY294002 (Fig. 4C).
These data suggest that relevant cytokines are capable of ele-
vating FasR expression in an AKT-dependent and NF-B-in-
dependent manner. These findings point to the physiological
relevance of AKT-mediated changes in FasR transcription and
cell surface expression.
We next monitored possible changes in apoptosis of LU1205
cells before and after pretreatment with TNF. Upon exposure
to FasL and cycloheximide (CHX), there was a marked increase
in apoptosis levels from 1% to 58% (Fig. 4D). Pretreatment with
TNF (10 ng/ml), which induces AKT activity, combined with
subsequent exposure to FasL and CHX further increased level
of apoptosis to 70%; pretreatment with TNF also elevated the
level of CHX-induced apoptosis from 4 to 15%. Increased Fas
surface expression upon TNF treatment coincides, albeit not
linearly, with actual apoptosis levels.
AKT-mediated Increase in FasR Expression Sensitizes Selec-
tive Melanomas to FasL-mediated Death—An increase in FasR
surface expression results in sensitization of the melanoma
cells to apoptosis by the FasL-Fas death signaling cascade (38).
In light of the observation that AKT mediates an important
regulatory role in FasR transcription and expression, we have
elucidated the changes in apoptosis elicited by AKT following
different external stimuli. The mouse melanoma cell lines
K1735 and SW1 provide a convenient system to monitor
changes in FasR expression and their effects on cell death (33,
38). Expression of STAT3 or Jun in their dominant negative
forms efficiently restored FasR expression and sensitization of
these cells to FasL-mediated death. On the basis of the identi-
fication of AKT as a key component in the regulation of FasR
expression, we established puromycin-resistant clones that sta-
bly express AKTmyr (Fig. 5A). K1735 cells that express AKTmyr
exhibit reduced activities of c-Jun and, to a lesser degree, of
STAT3 transcriptional activities, which coincided with in-
FIG. 3—continued
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creased FasR transcription (Fig. 5B). K1735 cells that express
AKTmyr exhibited an over 4-fold increase in the expression of
FasR on the cell surface (Fig. 5C). This finding coincides with
the observations made in the human melanoma cells, where
AKTmyr reduced Jun and STAT3 activities and elevated FasR
transcription and Fas cell surface expression. Increased FasR
expression sensitized these cells to FasL and CHX (from 14 to
33% apoptosis) but not to thapsigargin, an inhibitor of endo-
plastic reticulum-dependent Ca2-ATP required for apoptosis
(58) (Fig. 5D). Similar data were obtained with the SW1 cells,
where AKT expression resulted in elevated FasR expression
and sensitization to FasL-mediated but not thapsigargin-me-
diated death (not shown). These observations suggest that in-
crease in FasR expression due to AKT activities is sufficient to
sensitize selective melanoma cell lines to FasL-induced
apoptosis.
Unlike the responses seen in the K1735 or SW1 mouse mel-
anoma cells, AKT-increased FasR surface expression elicited
protection from apoptosis in response to FasL, UV, thapsigar-
gin, or the pharmacological inhibitors of PI3K or mitogen-
activated protein kinase in both WM9 (Fig. 5E) and LU1205
cells (not shown). These data suggest that despite changes in
FasR surface expression, AKT is capable of attenuating FasL-
mediated apoptosis in a selective set of melanoma cell lines. It
is likely that attenuated Fas-mediated apoptosis could be at-
tributed to the effects of AKT signaling on the processing of
FIG. 4. TNF induces endogenous AKT activity and up-regulates Fas surface expression in LU1205 melanoma cells. A, Western blot
analysis of AKT activity following TNF (10 ng/ml) treatment in the presence (added to cultures 1 h before TNF) or absence of LY204002 (50 M).
B and C, Fas surface expression of LU1205 and LU1205-IBN cells was determined before or 20 h after TNF (10 ng/ml) treatment in the
presence or absence of LY294002 (50 M). MFI is indicated. D, apoptosis levels in LU1205 cells that were pretreated with TNF (10 ng/ml) for 18 h
and subsequently treated with FasL (50 ng/ml) and CHX (10 ng/ml).
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caspases and/or other regulators of apoptosis (59).
Inhibition of Rac1 Increases FasR Expression—Among the
primary candidates for mediating AKT effects on JNK and Jun
as well as on STAT3 is Rac1. Earlier studies established the
ability of AKT to down-regulate the activity of Rac1, primarily
through phosphorylation on Ser71 (60). To directly assess the
role of Rac1 as the critical link between AKT and FasR, we used
the dominant negative form of Rac1, Rac1N17 (61). Forced
expression of Rac1N17 in normal fibroblasts but not in jun null
fibroblasts resulted in a marked increase in FasR surface ex-
pression (Fig. 6). Melanoma cells that express Rac1N17 also
exhibited a marked increase in the expression of surface FasR,
suggesting that Rac1 elicits negative regulation of FasR ex-
pression. Forced expression of Rac1N17 in ES cells also re-
sulted in elevated FasR expression, which was less pronounced
in the ES cells that lack one of the STAT3 alleles (and charac-
terized by lower levels of STAT3 protein) (Fig. 6), indicating
that Rac1 utilizes STAT3 to silence FasR expression. Both
STAT3- and c-Jun activities were demonstrated to be positively
regulated by Rac1 (62, 63). This finding coincides closely with
the notion that activity of Rac1 isoforms is often induced in late
stage tumors, which are expected to exhibit loss of FasR ex-
pression. In all, these results suggest that Rac1 may serve
as an intermediate in AKT-mediated suppression of FasR
transcription.
DISCUSSION
Advanced tumors often exhibit reduced or complete loss of
FasR expression, which coincides with greater resistance to
apoptosis and is believed to enable tumors to escape immune
surveillance (64). We previously identified cooperation between
STAT3 and c-Jun as the mechanism that underlies the loss of
FasR transcription and concomitant cell surface expression.
Since both STAT3 and c-Jun are ubiquitously expressed, the
present study was aimed at understanding the mechanism that
enables their cooperation, since it appears to take place in
FIG. 5. AKT overexpression up-regulates Fas levels and affects FasL-mediated apoptosis in melanoma cell lines. A, Western blot
analysis of K1735 melanoma cell lines stably transfected with empty vector (pBabe-puro) or AKTmyr. Anti-P-AKT, control anti-AKT, and anti-actin
Abs were used. B, effects of AKTmyr overexpression on AP1-dependent, STAT-dependent, or NF-B-dependent reporter activity and on Fas
promoter activity. The normalized ratio of luciferase/-galactosidase activity is shown. C, Fas cell surface expression in control and AKTmyr-
transfected melanoma cell lines was determined by fluorescence-activated cell sorting analysis. The percentage of Fas-positive cells is indicated.
D, induction of apoptosis in K1735-puro and K1535-AKTmyr cell lines following exposure to the indicated treatments. Analysis was carried out 48 h
after treatment. E, protection from FasL-mediated apoptosis in WM9 cells that express a constitutively active form of AKT. Effects of UVC
irradiation (60 J/m2) FasL (50 ng/ml) and CHX (10 g/ml) were determined 24 h after treatment. The effects of LY294002 (50 M), PD98052 (50
M), and thapsigargin (100 nM) on apoptosis induction were determined 48 h after treatment of WM9 cells that express the constitutively active
form of AKT. ns, nonspecific band.
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advanced tumors. Our studies, which relied on analysis of
intermediate stage melanoma tumor-derived cell lines, led us
to identify, albeit surprisingly, the role of the PI3K/AKT sig-
naling pathway in the regulation of FasR expression. Indeed,
tumor-derived cell lines including LU1205, WM9, and WM793
exhibit relative high levels of FasR and noticeable levels of
AKT in its active form. Constitutively active forms of either
AKT or p110, the catalytic subunit of PI3K, further increased
FasR transcription, monitored via FasR-luciferase activity,
with a concomitant increase in FasR expression on the cell
surface. Inhibition of the PI3K/AKT pathway via either the
dominant negative form of p85, the regulatory subunit of PI3K,
or PTEN or via the pharmacological inhibitor LY294002 re-
sulted in efficient suppression of FasR transcription and cell
surface expression. These observations clearly demonstrate
the role of PI3K and AKT in the positive regulation of FasR
transcription. Further support for the role of PI3K and AKT
in FasR-mediated apoptosis was shown in several cell sys-
tems, although the prevailing mechanism was not clearly
defined (65).
Further analysis revealed that AKT up-regulates FasR tran-
scription via down-regulation of STAT3 and c-Jun transcrip-
tional activities. First, the level of serine-phosphorylated forms
of Jun and STAT3 decreases upon AKT treatment, which co-
incided with decreased binding of the phosphorylated Jun and
STAT3 to the FasR promoter sequences in vitro. Noticeable
changes in tyrosine phosphorylation of STAT3 were only found
with the exogenously expressed form of STAT3, suggesting
that AKT may increase the activity of this dominant negative
form of STAT3, thereby providing an additional mechanism to
FIG. 6. RAC1N17 increases FasR surface expression. The indicated cell lines were transfected with the dominant negative form of Rac1,
Rac1N17, and GFP. 24 h later, cells were subjected to fluorescence-activated cell sorting analysis to monitor FasR surface expression in
GFP-positive cells of control (empty vector) or Rac1N17-transfected cells.
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explain inhibition of FasR transcription. Next, AP-1 and STAT-
dependent transcription of the luciferase reporter gene de-
creased in this case, further pointing to the decrease in tran-
scriptional activities of the two proteins. Changes in FasR
promoter activities were primarily mediated by c-Jun and
STAT3, since promoter sequences that were mutated in the
AP1 site or from which AP1 and GAS elements had been
deleted no longer responded to AKT signaling. The importance
of c-Jun for AKT-mediated derepression of FasR expression is
best illustrated in c-Jun null fibroblasts, where the constitu-
tively high level of FasR expression was no longer affected by
AKT. Further, a fully functional form of c-Jun was required to
decrease FasR expression, since the phospho-mutant form
failed to mediate these changes.
Taken together, these observations establish the important
role of c-Jun and STAT3 phosphorylation by their upstream
kinases for the regulation of FasR expression. JNK, which is
the primary candidate for Jun phosphorylation, is down-regu-
lated upon AKT expression. Along those lines, AKT was previ-
ously reported to elicit down-regulation of the stress kinase
p38, highlighting another pathway that is subject to negative
regulation by AKT (66). The link between AKT and JNK led us
to explore the role of Rac1, which is the target for AKT phos-
phorylation on Ser71, resulting in Rac1 suppression (60). In-
deed, inhibition of Rac1 activities was as efficient in increasing
FasR expression as constitutively active forms of AKT or p110.
These observations led us to propose that AKT may mediate its
effects on JNK via suppression of Rac1 activities. The ability of
Rac1 to elicit activation of STAT3 and c-Jun via SEK/MKK4
was demonstrated (61, 62, 67–71), suggesting that suppression
of Rac1 activities is expected to reduce STAT3 and c-Jun tran-
scriptional activities.
Although Rac1 was shown capable of altering both Tyr and
Ser phosphorylation of STAT3 (62), our experiments did not
reveal that in the melanomas examined here there is an effect
on basal levels of Tyr phosphorylation of STAT3; rather, there
is a notable effect on the Ser phosphorylation of both STAT3
and c-Jun. This suggests that the primary mechanism by which
AKT is capable of altering FasR transcription could be attrib-
uted to the serine phosphorylation of c-Jun and STAT3, both
are required for their transcriptional activities. The latter is
also supported by the notion that an inverse relationship be-
tween AKT and STAT3 phosphorylation was found in human
cancer cells (72). Our findings are also in line with former
studies, which demonstrated that the effect of PI3K may not be
limited to Tyr phosphorylation of STAT3, since Ser phospho-
rylation (of STAT1) was also reported (73). Furthermore, Rac1-
dependent Ser phosphorylation of STAT3 was also reported
(67, 74). Finally, AKT does affect tyrosine phosphorylation of
exogenously expressed STAT3, thereby providing some addi-
tional mechanistic insight to the relief of FasR expression in
these cells. The effect on STAT3 but not endogenous STAT3
Tyr phosphorylation could be attributed to the amount ex-
pressed, sensitivity of detection, or other possible causes, which
will be the subject for further studies. It is important to em-
phasize that impaired STAT3 transcriptional activity may not
always depend on the status of its Tyr phosphorylation (75).
The emerging model based on our studies suggests that
PI3K/AKT signaling utilizes Rac1 to down-regulate JNK and
consequently c-Jun as well as STAT3 transcriptional activities,
which otherwise cooperate to mediate suppression of FasR
transcription. As a result of AKT signaling and subsequent
Rac1 suppression, the cooperation between STAT3 and c-Jun is
impaired, thereby resulting in relief of FasR transcription and
increased FasR cell surface expression. According to this
model, the increase in AKT signaling, which takes place in
response to cytokines, UV (26), or altered PI3K signaling, will
result in elevated FasR expression; it is also expected that
elevated FasR will result in a concomitant sensitization of cells
to FasL-mediated death. This was indeed found to be the case
in some (K1735 and SW1) but not in other melanomas (WM9,
LU1205, and FEMX). The differences among the two sets of
melanomas studied here points to the possible existence of a
switch in AKT effector(s) or interference by other signaling
cascades, which alter the susceptibility to FasR-FasL-mediated
apoptosis. Interference of AKT-mediated increase of FasR is
expected to take place during tumor development and progres-
sion by any of the multiple signaling cascades that are linked to
or interfere with AKT signaling. For example, oncogenic Ras
was shown capable of inhibiting FasR expression via its effect
on AKT/PI3K pathways (76, 77). Similarly, growth factors that
are known activators of PI3K/AKT signaling, including hepa-
tocyte growth factor and epidermal growth factor, were shown
to be capable of down-regulating FasR-mediated death (78–
80). Further, a key component in the regulation of PI3K-AKT is
PTEN, which is either mutated or down-regulated in many
tumor types including melanomas (81–84). The relationship
between PTEN and Fas-dependent apoptosis is also illustrated
by the finding that PTEN/ mice exhibit impaired Fas re-
sponses, which could be restored upon the use of PI3K inhibi-
tors (81).
Another plausible target for changes that are expected to
override the AKT effect on FasR expression is c-kit; mutations
of c-kit have been identified in a variety of malignancies includ-
ing melanomas and were recently shown to result in constitu-
tive activation of STAT3 (86). Thus, tumors that harbor mutant
c-kit are also expected to exhibit down-regulation of FasR via
activated STAT3, which could override the effect of AKT sig-
naling. Finally, one must also consider other regulatory events,
which take place between Fas transcription and cell surface
expression (i.e. FasR trafficking). Among those, Par4, which is
altered in human prostate tumors, was recently found to affect
FasR trafficking (87).
Although we expect that K1735 and SW1, which exhibit
sensitization to FasL-mediated cell death following AKT-de-
pendent increase in FasR expression, represent a set of tumors,
the protection by AKT seen in the other melanomas raises a
question as to the possible physiological significance of elevated
FasR expression. First, it is likely that activation of AKT by
cytokines and DNA damage, as reported for epidermal growth
factor receptor and UV irradiation, serves to increase FasR as
a part of cell ability to undergo apoptosis, provided that other
AKT targets that serve antiapoptotic functions are suppressed.
Under constitutive expression of FasR, the scenarios that could
be envisioned include the possibility that elevated FasR in
parallel with protection from FasR-mediated death may serve
to lure the immune system. Along these lines, constitutive
expression of FasL in multiple myeloma cells was proposed as
a potential mechanism of tumor-induced suppression of im-
mune surveillance (88). Alternatively, it is possible that these
changes serve other functions required for the aggressively
progressing tumors, such as improved vascularization and con-
sequent angiogenic potential. Indeed, elevated vascularization
has been reported in tumors that overexpress AKT (89), and
AKT-expressing SW1 tumors in vivo exhibit a marked increase
in vascularization (data not shown). In contrast, inhibition of
STAT3 or c-Jun, which abolish cooperation among the two
protooncogenes to silence FasR, results in restored FasR ex-
pression and decreases tumor growth in vivo, due to an in-
creased degree of apoptosis (not shown).
Elevated levels of Rac1 or its isoform expression, which is
often reported to take place in human tumors, including human
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melanomas, is expected to also alter the activities of Rac1
effectors, including JNK and STAT3 kinases, resulting in in-
creased cooperation between STAT3 and c-Jun that inhibits
the activities of the FasR promoter. Inasmuch, Rac1 may also
serve as a focal point for the signaling cascade reported here.
Further, Rac1 has been implicated as an important target of
diverse signaling cascades including Rho, Ras, and c-kit, each
of which has been shown to undergo modifications during the
human tumor development and progression, including melano-
mas (90–93). Interestingly, the pathway identified in the pres-
ent study may be part of a feedback regulatory loop, since
STAT3 was reported capable of activating the PI3K cascade
(94). Similarly, Rac2 was shown capable of stimulating AKT in
primary mast cells (95), and the Rac1 ability to protect epithe-
lial cells against ankiosis was shown to depend on its activation
of PI3K/AKT (85). The existence of a positive feedback loop
suggests that via STAT3 or other Rac effectors AKT activation
may result in either inhibition of Rac1 (as one would expect to
take place upon its phosphorylation on Ser71) or constitutive
activation, under which AKT-mediated suppression of STAT3
and c-Jun may no longer be seen. It is expected that part(s) of
this feedback loop mechanism will be impaired in advanced
tumors.
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